Europe
Industry veterans including Craig Lipset will support the Castor’s vision to advance the future of clinical research
Bespoke approach generates high affinity antibodies and selects lead candidates with the strongest chances of success in the clinic
Sephara is changing the way automated analytical sampling as well as perfusion processes at the benchtop scale will be performed
Recipharm AB and Consort Medical plc have reached an agreement on the terms of a recommended cash offer by Recipharm Holdings Limited, a wholly-owned direct subsidiary of Recipharm, for Consort, a leading global drug delivery and device company and integrated contract development and manufacturing organisation
has continued to grow and will present its strategy for profitable growth moving forward, together with new financial targets from 2020, at Capital Markets Day in Stockholm.
Under the terms of the deal, Alkermes is paying $100 million in cash upfront. Rodin will be eligible for future payments of up to $850 million based on clinical and regulatory milestones and sales thresholds.
They will leverage Dicerna’s GalXC RNAi technology platform to explore more than 30 liver cell targets.
“The approval of Adakveo marks a new era in the treatment of sickle cell disease, a genetic condition that places an extraordinary burden of unpredictable pain crises on patients and their families,” said Susanne Schaffert, president of Novartis Oncology.
ZEISS and Kyoto University are intensifying their cooperation and have signed a new strategic research agreement.
OKRA Technologies, a leading provider of Artificial Intelligence driven analytics for global life sciences, announced they are joining the Veeva Technology Partnership Program and will be making their proprietary AI outputs available to Veeva CRM customers.
PRESS RELEASES